

## WeHealth by Servier and PathMaker Neurosystems form partnership for a Breakthrough Non-Invasive Neuromodulation Device for the Treatment of Spasticity

Paris, France & Boston, Massachusetts, United-States – January 9, 2019. [WeHealth by Servier](#), the e-health department of Servier Group, and [PathMaker Neurosystems](#), a pioneering clinical-stage bioelectronic medicine company, announced today the closing of a partnership agreement to develop and commercialize the first neuromodulation technology for non-invasive treatment of spasticity. The agreement between WeHealth and PathMaker establishes an exclusive worldwide distribution arrangement, excluding the U.S. and Japan, for the future PathMaker's [MyoRegulator™](#) device.

As part of the agreement, WeHealth will fund a recently initiated European clinical trial evaluating MyoRegulator for non-invasive treatment of lower limb spasticity secondary to stroke, which is currently being conducted by France's prestigious [Brain and Spine Institute](#) (Institut du Cerveau et de la Moelle Epinière – ICM) at the [Pitié-Salpêtrière Hospital](#) in Paris. WeHealth will also fund a larger European clinical trial intended to support reimbursement coverage. PathMaker will receive an upfront payment, clinical/regulatory milestones and commercial royalties from future sales of the device and disposables (single-use electrodes) in the Servier territories.

*“The MyoRegulator™ device has clear and groundbreaking benefits for patients with serious neurological conditions. Our partnership with PathMaker represents an opportunity for WeHealth to contribute to the advancement of a truly novel technology that is moving the field of bioelectronic medicine forward,”* said Dr. David Guez, General Director of WeHealth by Servier. *“This is WeHealth's first-ever partnership in the field of neurology”.*

*“We are excited by WeHealth's commitment to advancing next-generation treatments for chronic neuromotor conditions,”* said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. *“This significant partnership will provide a large number of patients with access to this breakthrough non-invasive treatment through Servier's international presence in more than 100 countries worldwide. We look forward to the positive impact this partnership will have on the patients waiting for meaningful and safe treatment, and on the development of our company.”*

### About Spasticity

Spasticity is a chronic condition characterized by painful muscle contractions and is common in patients following stroke, spinal cord injury, traumatic brain injury, cerebral palsy, multiple sclerosis and other neurological disorders. It affects an estimated 12 million people worldwide. Current treatments of the disorder include pharmacological agents, botulinum toxin injections and intrathecal baclofen, which are often costly and result in undesired side-effects.

### About MyoRegulator™ and DoubleStim™ technology

The MyoRegulator system is a microprocessor-controlled device that uses PathMaker's patent-protected DoubleStim technology to deliver synchronized stimulation at two sites along the neural axis via two pairs of disposable skin-surface electrodes. Through precisely sequenced and targeted multi-site stimulation directed at the spinal outflow and peripheral nerve leading to the muscle of interest, this proprietary approach modulates neural activity to suppress hyperexcitable spinal neurons involved in spasticity. At the Society for Neuroscience

meeting in November 2018, the largest annual meeting of the neuroscience field, clinical trial results from a recently completed US study at Northwell Health evaluating the effect of MyoRegulator treatment on post-stroke spasticity of upper limbs were recently presented.

#### **About Servier**

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (princeps drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information: [www.servier.com](http://www.servier.com)

#### **About WeHealth by Servier**

Launched in November 2016, WeHealth by Servier, the eHealth department of the Servier Group aims to improve the daily lives of patients and health professionals alike using digital means. WeHealth by Servier proposes innovative digital and connected solutions and services by making the most of collected data, to ensure better individual monitoring of the patient and to better prevent and predict the evolution of disease. In an open innovative approach, WeHealth by Servier identifies the most promising start-ups in e-health, in France and internationally, to co-develop solutions. In this way, WeHealth by Servier contributes to the creation of an ecosystem of partners to facilitate and accelerate the development, industrialization and distribution of innovations and to render them accessible to the greatest number.

For further information: [www.wehealthbyservier.com](http://www.wehealthbyservier.com)

Follow WeHealth by Servier on social media:



#### **About PathMaker Neurosystems**

PathMaker Neurosystems is a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with chronic neuromotor conditions. With offices in Boston (U.S.) and Paris (France), PathMaker Neurosystems is collaborating with world-class institutions to rapidly bring to market disruptive products for treating spasticity, paralysis and muscle weakness. More than 48 million patients in the U.S., Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson's disease and other neurological disorders. At PathMaker, they are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions. For more information, please visit the company website at [www.pmneuro.com](http://www.pmneuro.com).

#### **Press contacts:**

##### **Servier**

Sonia Marques : [media@servier.com](mailto:media@servier.com) – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13

Karine Bousseau : [media@servier.com](mailto:media@servier.com) – Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05

##### **PathMaker Neurosystems**

Sharon Correia, Sr. Vice President, Integrated Communications

LaVoieHealthScience

[scoreia@lavoiehealthscience.com](mailto:scoreia@lavoiehealthscience.com)

Anthony Karamourtopoulos

LaVoieHealthScience

[akara@lavoiehealthscience.com](mailto:akara@lavoiehealthscience.com)